Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission

Kensuke Usuki, Saiko Kurosawa, Naoyuki Uchida, Kazuaki Yakushiji, Fusako Waki, Eijo Matsuishi, Kumiko Kagawa, Tatsuo Furukawa, Yoshinobu Maeda, Manabu Shimoyama, Hiroatsu Ago, Yujiro Yamano, Shingo Yano, Naohito Fujishima, Yasushi Takamatsu, Tetsuya Eto, Michihiro Hidaka, Hitoshi Matsuoka, Takahiro Fukuda

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: A number of randomized trials in patients with AML in CR1 have been conducted and they showed that auto-HCT improves RFS but not OS, compared with chemotherapy. However, because these trials have had compliance problems, the value of auto-HCT still has not been clearly established. Patients and Methods: Using a database of 2518 adult patients with AML in CR1, we retrospectively analyzed the outcome of auto-HCT and compared it with intensive nonmyeloablative chemotherapy using landmark analyses. Results: In 103 auto-HCT recipients, OS and RFS at 3 years from treatment were 65% and 57%, respectively. Multivariate analysis showed that unfavorable risk cytogenetics and entry into CR1 after 2 courses of induction treatment predicted a poor outcome. Because the median time interval between CR1 and auto-HCT was 153 days, landmark analyses at 5 months after CR1 were performed to compare 1290 patients who received chemotherapy alone (median age, 52 years; range, 16-70) with 103 who received auto-HCT (median age, 48 years; range, 16-67). Auto-HCT improves 3-year RFS (58% vs. 37%; P <.001) but not OS compared with chemotherapy alone. Among patients with unfavorable risk cytogenetics or those who required 2 courses to reach CR1, there was no significant difference in RFS between the 2 groups. Conclusion: Auto-HCT can be considered as a postremission therapy for AML patients with favorable or intermediate risk cytogenetics who achieve CR1 after a single course of induction treatment.

Original languageEnglish
Pages (from-to)444-451
Number of pages8
JournalClinical Lymphoma, Myeloma and Leukemia
Volume12
Issue number6
DOIs
Publication statusPublished - Dec 2012

Keywords

  • AML
  • Autologous transplantation
  • CR1
  • Postremission therapy
  • inv(16)
  • t(8;21)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission'. Together they form a unique fingerprint.

  • Cite this

    Usuki, K., Kurosawa, S., Uchida, N., Yakushiji, K., Waki, F., Matsuishi, E., Kagawa, K., Furukawa, T., Maeda, Y., Shimoyama, M., Ago, H., Yamano, Y., Yano, S., Fujishima, N., Takamatsu, Y., Eto, T., Hidaka, M., Matsuoka, H., & Fukuda, T. (2012). Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission. Clinical Lymphoma, Myeloma and Leukemia, 12(6), 444-451. https://doi.org/10.1016/j.clml.2012.07.004